A 2024 meta-analysis revealed CD19 CAR-T monotherapy outperformed combined CD19 CAR-T/HSCT regimens in B-cell acute lymphoblastic leukemia (OR: 3.53; 95% CI: 1.26–9.88; high-quality evidence; Figure 1). Here, CD19 is linked to B-cell acute lymphoblastic leukemia.